IM-101 is under clinical development by ImmunAbs and currently in Phase I for Myasthenia Gravis. According to GlobalData, Phase I drugs for Myasthenia Gravis have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IM-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IM-101 overview
IM-101 is under development for the treatment of autoimmune disorders, paroxysmal nocturnal hemoglobinuria, myasthenia gravis, atypical hemolytic uremic syndrome, age related macular degeneration and optic nerve myelitis. It acts by targeting C5 protein.
ImmunAbs overview
ImmunAbs is an innovative biotechnology company specialized in antibody therapeutics. It is headquartered in Gangnam-gu, Seoul, Republic of Korea.
For a complete picture of IM-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
